The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer
progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor
abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized
clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use.
With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced
prostate cancer are now living longer with better quality of life. This article will review pre-clinical
and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms
of resistance and future directions for research.
Keywords: Prostate cancer, androgen receptor, abiraterone, enzalutamide.
Rights & PermissionsPrintExport